Gilead's Indian partnerships
Gilead Sciences is partnering with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab to enhance access in developing
countries to generic versions of its anti-HIV medicine, emtricitabine. Gilead will be providing technology transfer to its
partners for the manufacture of emtricitabine.
AstraZeneca's biologics arm, MedImmune, is restructuring its infectious disease and vaccines R&D and operations, resulting
in the closure of MedImmune's sites in Mountain View and Santa Clara in California (US). The company estimates that 300 jobs
will be affected. Of those, around 100 will move to other MedImmune locations.
Sanofi in antitrust lawsuit
A District Court in the US is moving forward to hear an antitrust suit filed by a group of doctors against Sanofi. The suit
alleges that Sanofi is attempting to monopolise the US meningococcal vaccine market. The physicians filing suit alleges that
Sanofi wrote language into their contracts to stifle competition within the childhood vaccine market.
Merck Serono Spinoff
Merck Serono is using €2.1 million to fund a new start up called Prexton Therapeutics. The funding is part of an initiative
to aid start ups and was launched following the company's recent restructuring activities. Prexton Therapeutics will employ
scientists to work around Merck Serono's R&D portfolio in the field of Parkinson's disease.
Sign up for our weekly e-Alert at
Generics rising in Brazil
With more drug patents reaching expiry, more generic-drug products have entered the Brazilian market in the past two years.
Brazil's generic-drug market grew by 32.2% in terms of sales volume between 2010 and 2011 alone, reaching R$8.7 billion (approximately
Russia aims for APIs
The Russian government is hoping that investments by multinational drug companies will help modernise drug production in the
country. Initially, the government expects foreign companies to help bolster innovation in drugs, but ultimately wants those
companies to assist in giving the country a platform for becoming a major producer of APIs.
India's pricing controversy
India's government recently announced plans to exercise stricter control over drug pricing in its domestic pharmaceutical
market. However, questions have been raised by the World Health Organisation about the plan to base ceiling prices for products
within individual therapeutic groups on the group's biggest seller.
China improves distribution
China's drug-distribution system has undergone development in recent years as the government directs efforts to encourage
reorganisation and mergers and acquisitions to improve the existing network. One of the main challenges however is that drug
distribution remains unregulated and users often obtain drugs from unknown or unauthorised sources.
Read more about emerging markets at